

CONSUMER PRODUCTS SERVICES DIVISION

# NARA FACTORY CO., LTD.

<b>Technical Report:</b>	(1215)173-0003
Date Received:	June 22, 2015

Initial Report Date:

July 15, 2015 Page 1 of 3

NARA FACTORY CO., LTD. 426 ANAMAI NGAMCHAROEN ROAD, BANGKHOONTIEN 10150 BANGKOK, THAILAND

Sample Description:	AIR HARDENING CLAY		
Manufacturer:	/	PO No.:	/
Buyer:	/	Style:	/
Country of Origin:	/	Country of Destination:	/
Color:	/	SKU No.:	/
Test Requested:	TOXICOLOGICAL RISK ASSESSMENT – USA	UPC Code:	1
	LHAMA – ASTM D4236		
Previous Report No.:	/	Lot No.:	/

## EXECUTIVE SUMMARY

The sample(s) **MEETS** the following requirement(s):

- Classification of not being toxic (acute/chronic), corrosive, a skin/eye irritant, or strong sensitizer as defined in the 16 CFR 1500.3(b)(5), (7) – (9) (FHSA regulations), when used as intended or under circumstances involving reasonable foreseeable misuse, based on a Toxicological Risk Assessment of the submitted product formulation by a Diplomate of the American Board of Toxicology (DABT).

The sample(s) was tested to the following requirement(s) and the data provided is for informational purposes only:

- Based on the provided art material formulation, the sample was evaluated to the requirements of the LHAMA regulation in accordance with 16 CFR 1500.14 and ASTM D4236 "Standard Practice for Labeling Art Materials for Chronic Health Hazards" by a Diplomate of the American Board of Toxicology (DABT).
  - Note:The submitted formulation would not be expected to pose any significant chronic adverse health effects to humans when it is used as intended or under circumstances involving reasonable foreseeable misuse. The product(s) will not require any additional chronic health hazard labeling according to ASTM D4236. The product(s) must bear the following statement:

"Conforms to ASTM D4236"

Bureau Veritas CPS Sdn Bhd Setia Business Park No. 7, Jalan Laman Setia 7/3, Taman Laman Setia, 81550 Gelang Patah, Johor, Malaysia Tel: (6)07- 5587266 Fax: (6)07- 5589266 Co.Reg.No: 614376-U Email:CustomerEnq.bvcpsMYHL@sg.bureauveritas.com Website: www.bureauveritas.com/cps This report is governed by, and incorporates by reference, the Conditions of Testing as posted at the date of issuance of this report at <a href="http://www.bureauveritas.com/cps">http://www.bureauveritas.com/cps</a> and is intended for your exclusive use. Any copying or replication of this report to or for any other person or entity, or use of our name or trademark, is permitted only with our prior written permission. This report sets forth our findings solely with respect to the test samples identified herein. The results set forth in this report are not indicative or representative of the quality or characteristics of the lot from which a test sample was taken or any similar or identical product unless specifically and expressly noted. Our report includes all of the tests requested by you and the results thereof based upon the information that you provided to us. You have 60 days from date of issuance of this report to notify us of any material error or omission caused by our negligence, provided, however, that such notice shall be in writing and shall specifically address the issue you wish to raise. A failure to raise such issue within the prescribed time shall constitute your unqualified acceptance of the completeness of this report, the tests conducted and the correctness of the report contents.



NARA FACTORY CO., LTD. Technical Report: **(1215)173-0003** Initial Report Date: July 15, 2015 Page 2 of 3

#### Exposure Assessment:

Consideration was given to consumer exposure with intended product use and under circumstances involving reasonable foreseeable misuse. Intentional product misuse was not considered within the scope of the assessment. This evaluation was conducted under the assumption that potential acute exposure to product ingredients is through the dermal route and possibly the oral route through accidental ingestion. The inhalation route was not evaluated since none of the chemicals in the product formulation were considered sufficiently volatile for inhalation exposure. Chronic exposure is only considered to occur via the dermal route given that chronic accidental ingestion is unlikely.

### Considerations:

It was assumed that all product formulation details are accurate and that there are no additional ingredients that are not listed (note: chemical testing was not conducted as part of this product evaluation and chemical analyses data were not provided in support of this evaluation). It was also assumed that any ingredients provided in the product formulation do not contain any impurities and/or contaminants (e.g., heavy metal(s) or lead) or infectious agents that would cause toxicity in a consumer who may be exposed to them. This product was not evaluated for toxicological considerations related to physical or chemical properties of the formulation (e.g., pH, viscosity, volatility) and potential for physical injury (e.g., choking hazard, aspiration risk, or mechanical irritation) was not considered.

- Note: This evaluation does not constitute a regulatory review and does not address the requirements for labeling, unless otherwise indicated.
- Note: This evaluation is relevant solely to the conditions described herein. Any substitution of ingredients, increase in ingredient concentrations, or change in use pattern will necessitate a new evaluation.
- Note: The Toxicological Risk Assessment(s) and LHAMA evaluation were performed at a Bureau Veritas CPS approved subcontract lab on July 13, 2015.

# **BUREAU VERITAS CPS SDN BHD**

Technical Inquiries: Koo Chieh Voon Tel: 607-5587266 ext 108 email: <u>chiehvoon.koo@sg.bureauveritas.com</u>

PREPARED BY:

**APPROVED BY:** 

KOO CHIEH VOON HARDLINE ASSISTANT MANAGER

SITI DZULAIHA TESTING TECHNICIAN



NARA FACTORY CO., LTD. Technical Report: **(1215)173-0003** Initial Report Date: July 15, 2015 Page 3 of 3

